key: cord-1033084-uh5yqhzv authors: Goel, Ruchika; Eapen, C.E. title: Recognizing dysfunctional innate and adaptive immune responses contributing to liver damage in patients with cirrhosis date: 2021-10-14 journal: J Clin Exp Hepatol DOI: 10.1016/j.jceh.2021.10.001 sha: 98d851b45b28bbe5079e1c011335e2a30b434e2d doc_id: 1033084 cord_uid: uh5yqhzv The human host immune system wards off attack by enemy such as viruses by mounting an inflammatory response which may sometimes injure self-tissues. Dysfunctional immune/inflammatory response by the host may affect the functioning of vital organs. The largest number of innate immune cells in the body resides in the liver. On encountering a new insult or injury to the liver, the innate immune system responds quickly to counter it. Acute liver insults may trigger acute liver failure or acute on chronic liver failure, these disorders are associated with predominant innate immune response. Activation of reticulo-endothelial system (part of innate immune response) predicts short term and medium term survival in patients with acute on chronic liver failure. Liver diseases associated with aberrant adaptive immune response like autoimmune hepatitis respond well to treatment with steroids and other immunosuppressants, while those associated with innate immune dysfunction like acute on chronic liver failure do not respond well to steroids; recent reports suggest that the latter disorders may respond to therapeutic plasma exchange. How does the immune system in a patient with liver disease respond to SARS CoV2 infection? While commonly used tests in routine clinical practice provide clues to activation of different arms of immune response in patients with cirrhosis, specialized tests may help characterize this further. This review discusses the tests which reflect aberrant immune responses in patients with cirrhosis and treatment of the same. The host immune system is a vital department of our body and the moment a person dies, this department is disbanded, leaving the physical human body accessible to microbial invasion, destruction, and decay. In times of peace, the presence of defence forces is not obvious in a society; similarly, in the absence of enemy (microbial) invasion, the importance of immune system is often not appreciated in the human body. As with any efficient defence force, immune responses to tackle the constant microbial attack are silent and not discerned by the host. Similar to the nation's army, navy and air force; the human body has innate and adaptive immune responses. Skin, gastrointestinal tract and lungs -where the human body interfaces with external environment -need constant surveillance to sense enemy attack. How do these sensors recognize the enemy from the nation's own? In predisposed individuals, the immune response starts to train its ammunition onto host antigens (termed autoimmune disease), resembling a "civil war". It is important to recognize the tell-tale signs of this civil war, its causative factors and implement interventions to quell this uprising. If a new enemy -never before encountered -attacks, how will the host immune system respond? In this review, we describe how to recognize dysfunctional innate and adaptive immune responses by clinical features and appropriate investigations in patients with cirrhosis and therapeutic interventions to address these. Innate immune response lacks antigen specificity and generally lacks memory, while adaptive immunity is antigen specific, diverse and has memory 1 . Innate immune system ("rapid action force") is present from birth and responds immediately (within minutes) of sensing the enemy (microbe). In contrast, adaptive immune system is slow to respond (after days to weeks of exposure) to microbe and comprises of responses learned from prior exposure to microbial antigen; they are not present from birth. Some of the rapid action force (like neutrophils) move immediately to the site of enemy attack. In contrast, heavyweight guns ("artillery") like macrophages are difficult to shift rapidly to the scene of attack and are best placed in strategic locations which are constantly vulnerable to enemy attack. Both innate and adaptive immune systems have cells ("soldiers") and humoral factors (like cytokines, immunoglobulins) to fight the microbial enemy. Effector cells of innate immune response include neutrophils, eosinophils, basophils, macrophages, monocytes, mast cells, natural killer (NK) cells, and NK T cells; while adaptive immune cells are T lymphocytes and B lymphocytes 2 . NK cells -traditionally defined as innate immune cells -help co-ordinate innate and adaptive immune responses 3 . Innate immune cells recognize lipopolysaccharide and peptidoglycan components of microbes termed as pathogen associated molecular patterns (PAMPs) by pattern recognition receptors. To exemplify, toll like receptor 4 (TLR4) on surface of macrophages recognize lipid A / lipopolysaccharide constituents of cell wall of gram-negative bacteria. Cytosolic pattern recognition receptors such as NOD like receptors in innate immune cells recognize PAMPs and endogenous danger associated molecular patterns (DAMPs) derived from damaged and dying cells. On sensing DAMPs or PAMPs, effector arms of innate immune responses are activatedincluding cells which phagocytose microbes (ex: neutrophils, macrophages) and cells which release pro-inflammatory chemokines and cytokines (ex: neutrophils, macrophages, dendritic cells, NK cells). Specific receptors on T and B lymphocytes recognize peptide fragments presented alongwith human leukocyte antigen (HLA) by antigen presenting cells. Interaction of T cell receptor with peptide-HLA complex leads to T cell differentiation into T helper cells (which can activate B cells to trigger humoral immune response) and cytotoxic T cells (which provide cellular immunity). In mid-1960s, reticulo-endothelial system was re-named as mononuclear phagocyte system 4 . These two terms refer to over-lapping, but distinct parts of the immune system. Mononuclear phagocyte system refers to cells like macrophages, monocytes and dendritic cells while excluding endothelial cells 5, 6 . As they appear net-like on electron microscopy, macrophages are referred to as "reticular" cells. The term reticulo-endothelial system emphasizes the anatomical proximity and interlinked functioning of tissue resident macrophages and endothelial cells. Kupffer cells (macrophages) reside next to endothelial cells in liver sinusoids. Both cells share important functions -they participate in innate immune responses, and remove waste products from blood traversing the liver sinusoidal filter. Kupffer cells remove insoluble waste by phagocytosis while liver sinusoidal endothelial cells remove soluble macromolecular and colloidal (< 100 nm) waste by endocytosis 7 . When do we refer to some liver diseases as "auto"immune? The "auto" in autoimmune diseases may imply two explanations. When host immune system targets the host itself, we use the term autoimmune diseases. At present, the term 'autoimmune diseases' is restricted to those diseases wherein dysfunctional adaptive immune responses (like self-reactive CD4+ and CD8+ T cells) target self-antigen. Continued immune mediated damage to the host liver initiated by a known trigger such as alcohol and drugs, even after the triggering factor is no longer present in the body, is termed as immune mediated liver disease and not autoimmune disease, even though the insulted organ is still one's own liver. Immune mediated liver diseases: When immune response to chronic hepatitis B infection damages liver or kidneys, we use the term "immune -mediated damage" to the self (this is not termed autoimmune hepatitis or glomerulonephritis, the preferred term is immune-mediated hepatitis or glomerulonephritis due to hepatitis B infection) 8 . Liver diseases caused by viruses and idiosyncratic drug reactions are examples of diseases considered as immune mediated liver diseases s 9,10 . The host response to injury is inflammation. Recently, the term "auto-inflammatory" disease has been coined 11, 12 . These inflammatory disorders are characterized by innate immune response, while the adaptive immune system is not activated (autoantibodies and autoreactive T cells are absent). Hereditary periodic fever syndromes were initial disorders identified to have these peculiar features; however, this term now includes diseases like neonatal onset multi-system inflammatory disease, linked to mutant cryopyrin. Dysregulated sense-stressing pathways may also be linked to auto-inflammatory diseases. Auto-inflammatory and autoimmune classification are not watertight compartments as there is a component of both innate and adaptive system activation in most diseases with one compartment predominating over the other 13 . The closely intertwined innate and adaptive immune systems means that patients with liver diseases due to dysfunctional adaptive immune response (ex: autoimmune hepatitis [AIH]) will also have innate immune responses activated. Similarly, patients with severe alcoholic hepatitis -a disorder of predominant innate immune attack on liver -also have adaptive immune responses activated. Adaptive immune cells (T and B lymphocytes) differentiate and mature in primary lymphoid organs (bone marrow, thymus) and secondary lymphoid organs (spleen, lymph nodes, mucosa associated lymphoid tissue). The liver mounts a strong innate immune response and weak adaptive immune response. It is also important in inducing immunological tolerance. Hence, liver can be considered as an (predominantly innate) immune organ 7,14 . The dual blood supply to the liver from portal and systemic circulation and fenestrated sinusoids facilitate rapid exchange of immunogenic metabolites and toxins from blood into hepatocytes. Hepatocytes and different immune resident cells in liver co-ordinate phagocytosis of pathogens by pattern recognition receptors and scavenger receptors. Lipopolysaccharide, lipoteichoic acids, glycopeptides are examples of PAMPs recognized by pattern recognition receptors like TLRs (located on the surface or in endoplasmic reticulum), NOD like receptors and retinoic acidinducible gene I receptor (located in cytoplasm). The liver is enriched with innate immune cells (Table 1) . Liver dendritic cells and macrophages mediate effective antigen presentation to stimulate adaptive immune response 15 . Lymphocytes in the liver are selectively enriched with NK cells and NK T cells 16 . In healthy liver, these cells regulate Th1 and Th17 cells by releasing anti-inflammatory cytokines predominantly IL10. Kupffer cells account for about 90% of the fixed macrophages in the body. These innate immune cells clear hepatotrophic pathogens and metabolites (DAMPs) while leading to immune tolerance by anti-inflammatory cytokines (IL10, TGFβ, IL13). Hepatic endothelial cells also have innate immune function as suggested by expression of surface TLRs and secretion of chemokines) 18 . The distinctive anti-inflammatory phenotype of liver resident innate cells is due to differentiation of myeloid and lymphoid progenitors / immature hepatic stellate cells in the liver. Neutrophils, a major innate immune cell, are mostly absent in the liver in health; in contrast, neutrophilic infiltration surrounding hepatocytes is a typical histological feature in severe alcoholic hepatitis. The signalling by pattern recognition receptors and release of chemokines are responsible for migration of neutrophils to the inflamed liver. Hepatocytes contribute to innate immune response by producing most innate immune proteins like complements 7 and also secrete soluble pathogen recognition molecules such as C-reactive protein (CRP) 19 . CRP refers to a protein which reacts to C-polysaccharide of pneumococcal cell wall. The liver harbors many antigen presenting cells which are professional (like dendritic cells and Kupffer cells) and non-professional (like liver sinusoidal endothelial cells and hepatic stellate cells). When antigens are presented by these cells to T cells, the latter can undergo apoptosis, anergy, or differentiate into regulatory T cells. The remarkable tolerance of liver to many gut derived antigens is mediated by hepatic dendritic cells and regulatory T cells. The balance between inflammatory and anti-inflammatory cytokine milieu maintains immune tolerance of liver while retaining the ability to clear gut derived pathogens and toxic metabolites. It is important for the hepatic immune system to override immune tolerance to respond to pathogens and tumours. Among the different solid organs transplanted, liver is the most tolerogenic organ. How liver transplant tolerance occurs in not well understood; the local microenvironment and hepatic immune cells are likely to be important 20 . The use of immunosuppressive drugs to prevent rejection of the transplanted liver is beyond the scope of this review. Different innate lymphocyte populations like NK cells, CD56(+) T cells, NK T cells, γδ T cells, and mucosa associated invariant T cells accumulate in the liver. Innate lymphocytes recognize conserved metabolites derived from microorganisms and host cells and kill target cells and/or activate other immune cells. Innate lymphocytes can promote maturation of antigen presenting cells, leading to immunogenic T cell responses. These cells may override hepatic immune tolerance to autoantigens, leading to induction of autoreactive T cells targeting the liver, causing autoimmune liver disease. During inflammation, triggers like alcohol, virus, toxins and cholesterol lead to metabolic reprogramming of innate and adaptive immune cells altering their phenotype to inflammatory cells. However, imbalance between activities of immune regulatory cells and effector T cells may lead to autoimmune disease 15 . Apart from innate immune cells, adaptive lymphocytes like MHC restricted CD4+, CD8+ T cells, both activated and memory phenotype, and B cells also enrich liver. In health, these cells undergo apoptosis/ deletion, (thus the liver is a "graveyard of T cells") or acquire antigen specific tolerance due to antigen presentation by tolerogenic hepatic dendritic cells and nonprofessional APCs in liver (hepatocytes, endothelial cells) 21, 22 . In patients with cirrhosis and more so, in ACLF patients, bacterial overgrowth and inflammation in the intestines and bacterial translocation lead to many PAMPs alongwith reduced detoxification of bacterial lipopolysaccharide. These are recognized by TLRs and NOD like receptors on Kupffer cells and results in further activation of innate immune cells like neutrophils and production of pro -inflammatory cytokines (TNFα, IL8, Interferons) and CXCL chemokines. DAMPs like high mobility group box 1 (HMGB1) protein, ATP complexes, uric acid, cholesterol, triglycerides, succinates and products of liver cell necrosis are increased in decompensated cirrhosis. The DAMPs along with IL1α and IL33 activate pattern recognition receptors like advanced glycation end products specific receptors, TLRs 2 and 4, siglec-10, syndecan-3, resulting in sterile inflammation by activating innate immune system 23 . With such a large contingent of innate immune cells located in the liver, it is likely that dysfunctional innate immune response may cause liver damage. Overwhelming of the scavenging capacity of reticulo-endothelial system located in liver sinusoids as a consequence of acute liver insult in patients with cirrhosis may result in acute on chronic liver failure (ACLF) 23 . How do we recognize the liver diseases associated with innate immune dysfunction and those with adaptive immune dysfunction? Once these syndromes are recognized by appropriate tests, then treatment can be planned, aimed at these dysfunctional immune mechanisms. Autoimmune hepatitis (AIH): Raised serum immunoglobulin G levels and infiltrates of lymphocytes and plasma cells in liver biopsypart of criteria to diagnose AIHpoint to dysfunctional adaptive immune response causing AIH. The postulated self-antigens targeted in AIH are asialoglycoprotein receptor located on hepatocyte surface in type 1 AIH and CYP 450 2D6 and other antigens in hepatocyte microsomes in type 2 AIH 24,25 . HLA-DR3 and HLA-DR4 increase the risk of type 1 AIH in Caucasians. HLA haplotype DRB1*0301-DRB3*0101-DQA1*0501-DQB1*0201 is associated with type 1 AIH 26 . Type 1 AIH was associated with HLA DRB1*04 in northern India and with HLA B27, HLA Cw6 and HLADR*01,*14,*15 and *07 in western India 27, 28 . Dysfunction of innate immune cells like NK T cells, monocytes, Kupffer cells and dendritic cells also occur in AIH 29 . Molecular mimicry (virus or drug mimicking hepatocyte antigens) may confuse host immune sensing mechanisms in AIH. Viruses like hepatitis viruses, Epstein Barr virus, measles virus and drugs like minocycline, atorvastatin, methyldopa, nitrofurantoin and pemoline may trigger AIH. Precise definition of these liver diseases is important 30 . It is interesting to note that CYP 450 2D6, the postulated target antigen for type 2 AIH, is a drug metabolizing enzyme. PSC may occur secondary to portal bacteremia, biliary infection and toxic bile acids. Anti-neutrophil cytoplasmic antibodies (ANCA) exemplify the activation of humoral arm of adaptive immune system in PSC 31 . pANCA, anti-PR3 ANCA and IgA antibodies against glycoprotein-2 indicate poor prognosis in PSC patients 32 . In addition to HLA, other genes close to HLA region (TNFᾳ, MHC-1 chain-related gene family) are also considered as susceptibility genes for PSC 32 . Loss of tolerance to a ubiquitous mitochondrial antigen which is a residue of pyruvate dehydrogenase complex is postulated to drive PBC. This loss of tolerance maybe mediated by molecular mimicry and generation of neoantigen due to modification of self-antigen 33 . Overlap syndromes: The dysfunctional adaptive immune response may attack more than one of the above target antigens in the liver, the resulting clinical phenotype wherein AIH, PSC and PBC can overlap with each other is termed "overlap syndrome". These are fibro-inflammatory multisystem disorders with exuberant expansion of IgG4 class switched cells and plasma cells. Classically described as autoimmune disorder with varied T-helper cell responses, innate immune activation may also contribute to fibrosis, thus proposing an overlap with auto -inflammatory component [34] [35] [36] . Liver involvement in IgG4 RD maybe due to AIH, secondary to IgG4 related sclerosing cholangitis or type 1 autoimmune pancreatitis associated hepatopathy 37, 38 . Acute on chronic liver failure (ACLF): Organ failures and high short-term mortality in ACLF patients may be due to exaggerated systemic inflammatory response. Innate immune response including reticulo-endothelial system activation may drive the clinical syndrome of ACLF 35 . Raised levels of plasma von Willebrand factor (VWF), a marker of endothelial activation, correlate with severity of liver disease and predict outcome in patients with ACLF as defined by Asia Pacific Association for Study of Liver (APASL) 39 . Raised plasma VWF levels and serum soluble CD163 and soluble mannose receptor (sMR) levels correlate with disease severity and predict death in patients with ACLF, as defined by European Association for Study of Liver (EASL) [40] [41] [42] . Thus, ACLF diagnosed by criteria proposed by APASL or EASL gives clue to presence of over -active innate immune response. How does innate immune activation worsen liver damage in patients with cirrhosis who develop ACLF? The exact mechanism is not well understood at present. Overwhelmed scavenging capacity of reticulo -endothelial cells may lead to inflammatory debris clogging the liver sinusoids, reduce perfusion in liver microcirculation and aggravate liver failure in these patients 43 . Hemophagocytic lymphohistiocytosis is a hyper-inflammatory syndrome due to aberrant activation of macrophages, NK cells and T cells 44, 45 . When this occurs secondary to lymphoproliferative disorder, infections, auto-inflammatory diseases or autoimmune diseases, it is termed as macrophage activation syndrome 46,47 . The clinical phenotype is usually multi-organ inflammation predominantly hepatitis, cytopenia and unremitting fever. Hemophagocytic syndrome can be seen in patients with viral hepatitis, AIH and drug induced liver injury 48, 49 , and may be associated with adverse outcome in patients with cirrhosis 50 . Some of the current criteria to diagnose macrophage activation syndrome exclude patients with certain liver diseases. For example, criteria to diagnose macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis have infectious hepatitis as an exclusion criterion 51 . If pre-existing liver disease is an exclusion criterion to diagnose macrophage activation syndrome 52 , then these criteria cannot be applied to study innate immune activation in ACLF patients, who have pre-existing cirrhosis. (Table 2) The predominant type of immune cells infiltrating the liver seen on liver biopsy, analyzing the peripheral white blood cells on routine tests and by more specialized tests and study of circulating soluble markers of immune activation can help recognize if any of the arms of the immune system are activated in patients with liver diseases. Inflammatory infiltrate, if seen on liver biopsy, reflects the predominant immune system (innate versus adaptive) which is activated and maybe contributing to liver disease. The immune cells recruited from the blood stream into the liver parenchyma, often start infiltrating at the portal tracts. Neutrophilic infiltrate in liver biopsy is a typical feature of severe alcoholic hepatitis (i.e. over-active innate immune response). Eosinophilic infiltrate on liver biopsy in patients with idiosyncratic drug allergy again suggests over-active innate immune response in the liver. Presence of lymphocytes and plasma cells infiltrating the portal tracts on liver biopsy in AIH points to adaptive immune response attacking the liver. In hospitalized patients with cirrhosis and with ACLF, the ratio of neutrophils (innate immune cells) to lymphocytes (adaptive immune cells) -a marker of immune dysregulation -independently predicted 90-day mortality 53, 54 . Specialized tests can identify which subsets of T or B lymphocytes, neutrophils or macrophages are turned on or off. For example, pro-inflammatory and anti-inflammatory macrophage phenotypes can be recognized by flow cytometric studies in ACLF patients. Patients with ACLF have leukocytosis, neutrophilia, and lymphopenia. Whole blood RNA expression studies showed neutrophilia, higher proportions of macrophages, M0-like monocytes and lower proportions of memory lymphocytes, CD8 T cells and NK cells as the hallmark of ACLF 55 . Raised levels of markers of macrophage activation like serum ferritin (typically > 500 mcg/L), soluble CD163 (a hemoglobinhaptoglobin scavenger receptor) and sMR indicate activated innate immune system in cirrhosis and ACLF patients 42 . Elevated serum CD25 level indicates T cell activation, which can happen as a downstream stream event in macrophage activation. Raised plasma VWF levels signify endothelial activation in cirrhosis and in ACLF patients 39 . Specifically, these markers document reticulo -endothelial activation in these liver diseases. Raised levels of serum IgG in AIH indicate adaptive immune response. (Table 3) J o u r n a l P r e -p r o o f The blood levels of inflammatory markers are raised in patients with cirrhosis and are even higher in patients with ACLF. Are these inflammatory markers sequelae of liver injury or do they influence progression of liver disease? Severe alcoholic hepatitis often precipitates ACLF 56 . Markers of reticulo -endothelial activation correlate with liver disease severity and predict death, independent of Model for End-Stage Liver Disease (MELD) scores, in patients with severe alcoholic hepatitis 57, 58 . Prognostic ability of these indices, suggest that these inflammatory markers may contribute to worsening of severity of liver disease in these patients. In a systematic review of 6 studies including 765 patients (cirrhosis: 715 patients; ACLF: 50 patients), elevated plasma levels of VWF antigen at baseline independently predicted mortality over 25.6 months (23.6-33 months) in patients with cirrhosis (area under curve: 0.74; 95% confidence interval: 0.7 -0.79) with an optimal cutoff of 318% (216-390%), median (range). 59 Plasma VWF levels also predicted short-term (over 7 days) mortality in ACLF patients. Combining VWF levels to MELD score increase the prognostic value in patients with end-stage liver disease 40 . In patients with cirrhosis and ACLF, serum levels of CD163 and sMR increased incrementally with worsening disease severity. Both sCD163 and sMR independently predicted mortality at 1-3 months and at 6 months and had equal or better predictive accuracy than MELD score. Combining these macrophage activation markers to MELD score also improved the prognostic ability 42, 50 . Chronic hepatitis due to AIH is caused by dysfunctional adaptive immune response and responds well to treatment with prednisolone. In contrast, patients with ACLF due to AIH do not respond so well to steroid treatment 60, 61 . Similarly, patients with alcohol related ACLF tolerate steroids poorly and it is not certain if steroid treatment is beneficial or deleterious in them 62 . Recent evidence suggests that plasma exchange may benefit patients with liver disorders with predominant innate immune dysfunction (like acute liver failure, ACLF) 63 . Depending on the volume of plasma exchanged at each session to treat these liver failure syndromes, plasma exchange can be classified as high volume, standard volume and low volume [64] [65] [66] [67] . Plasma exchange improves transplant free survival in patients with acute liver failure [64] [65] [66] and ACLF [66] [67] [68] [69] [70] [71] . The beneficial effect of plasma exchange in these liver disorders with predominant innate immune response may be by attenuating innate immune activation and removing inflammatory debris including macromolecules like VWF 43 . J o u r n a l P r e -p r o o f The rapidity of the response needed and the lack of prior memory of such an enemy encountered in the past suggests that innate arm of the immune system will respond to the first exposure to a new enemy (like a new virus) not encountered before. Acute liver injury / failure is predominantly caused by paracetamol overdose in the West; in contrast, this is mostly caused by hepatitis E in northern India and rodenticide ingestion in southern India 71-74 . Raised plasma VWF levels correlate with disease severity and predict inhospital survival in patients with rodenticide induced hepatotoxicity, suggesting that innate immune activation may contribute to pathogenesis of rodenticidal hepatotoxicity 75 . How does the host immune system respond to severe acute respiratory syndrome coronavirus 2 (SARS CoV2) infection in a patient with cirrhosis? 76 Coronavirus disease of 2019 (COVID- 19) is characterized by pulmonary endotheliopathy as the virus invades lung endothelium 77, 78 .In a study of reticulo-endothelial activation in 143 hospitalized COVID-19 patients, none of whom had liver disease, levels of markers of activation of macrophages (serum CD163, serum ferritin) and endothelium (plasma VWF) increased with increasing COVID-19 severity. Only baseline VWF levels independently correlated with disease severity and predicted in-hospital mortality 79 . Plasma exchange and low dose steroid may help severe / critical COVID-19 patients, by reducing levels of VWF and other inflammatory debris in circulation 80 . SARS CoV2 does not appear to be hepatotrophic, though the viral entry receptor (angiotensin converting enzyme -2) has been described in cholangiocytes. Acute hepatitis in COVID-19 patients may also be due to drugs or as part of systemic inflammatory response. Cirrhosis increases risk of death in patients with COVID-19 81 . Can exposure to SARS CoV2 or COVID-19 vaccine trigger autoimmune hepatitis 82, 83 ? It is unclear from preliminary reports if this association has any causative link. A study of 110 AIH patients with COVID-19 found new onset liver injury in 37% of patients. Severity of COVID-19 disease and mortality were similar in AIH patients and in those with chronic liver disease due to other causes. Continued immunosuppressive treatment for AIH did not increase risk for severe COVID-19 but reduced new onset liver injury during COVID-19 84 . Liver disorders due to dysfunctional adaptive immune response like AIH respond well to steroid treatment. In contrast, those associated with dysfunctional innate immune response, like ACLF, respond poorly to steroids. The overwhelmed scavenging function of reticulo-endothelial cells in liver sinusoids may contribute to progression of liver failure in ACLF patients and plasma exchange may help by removing some of the inflammatory debris which clog the liver microcirculation in these patients. Appropriate tests help us to identify which arm of immune system is predominantly activated in patients with cirrhosis and select patient for appropriate Trained immunity, tolerance, priming and differentiation: distinct immunological processes Innate immune cells in cirrhosis NK cells at the interface between innate and adaptive immunity Mononuclear phagocytic system: new classification of macrophages, monocytes and of their cell line A calculated response: control of inflammation by the innate immune system Human mononuclear phagocyte system reunited Liver: An organ with predominant innate immunity Immune-mediated Liver Injury in Hepatitis B Virus Infection Immune-mediated liver injury Mechanisms of immunemediated liver injury Lighting the fires within: the cell biology of autoinflammatory diseases The Relationship between NALP3 and Autoinflammatory Syndromes A proposed classification of the immunological diseases The liver as an immunological organ The current immune function of hepatic dendritic cells Functional heterogeneity in liver and lung macrophages The immunophenotype of antigen presenting cells of the mononuclear phagocyte system in normal human liver--a systematic review Liver sinusoidal endothelial cells -gatekeepers of hepatic immunity Innate immune recognition: mechanisms and pathways Understanding, predicting and achieving liver transplant tolerance: from bench to bedside Liver immunology and its role in inflammation and homeostasis Immunity, tolerance and autoimmunity in the liver: A comprehensive review The Acute-on-Chronic Liver Failure Syndrome, or When the Innate Immune System Goes Astray The human hepatic asialoglycoprotein receptor is a target antigen for liver-infiltrating T cells in autoimmune chronic active hepatitis and primary biliary cirrhosis Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview Autoimmune hepatitis HLA DRB1 Alleles Discriminate the Manifestation of Autoimmune Hepatitis as Type 1 or Type 2 in North Indian Population HLA genotyping in type-I autoimmune hepatitis in Western India Altered function of monocytes/macrophages in patients with autoimmune hepatitis Case definition and phenotype standardization in drug-induced liver injury Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis Association of primary sclerosing cholangitis with HLA-B8 Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis IgG4-related disease: How to place it in the spectrum of immunemediated and rheumatologic disorders? New insights into immune cells cross-talk during IgG4-related disease Cytokines produced by innate immune cells in IgG4-related disease Autoimmune hepatitis and IgG4-related disease Review of primary sclerosing cholangitis with increased IgG4 levels Plasma von Willebrand factor levels predict in-hospital survival in patients with acute-on-chronic liver failure The Addition of C-Reactive Protein and von Willebrand Factor to MELD-Na Improves Prediction of Waitlist Mortality The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF) Targetting Raised von Willebrand Factor Levels in Liver Diseases: Opening Up Newer Therapeutic Avenues HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis Recommendations for the management of hemophagocytic lymphohistiocytosis in adults Hemophagocytic Lymphohistiocytosis Secondary to Acute Hepatitis E Infection: A Rare Association Hemophagocytic Lymphohistiocytosis Associated with Hepatitis A and Hepatitis E Co-infection Autoimmune-associated hemophagocytic syndrome originating from autoimmune hepatitis with a successful response to therapy Drug-induced liver injury with autoimmune features complicated with hemophagocytic syndrome Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure Paediatric Rheumatology International Trials Organisation; Childhood Arthritis and Rheumatology Research Alliance Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative Clinical features and correct diagnosis of macrophage activation syndrome Neutrophil-to-Lymphocyte Ratio Associates Independently With Mortality in Hospitalized Patients With Cirrhosis Serum C-reactive protein and neutrophil-to-lymphocyte ratio as predictors of survival in cirrhotic patients with systemic inflammatory response syndrome and bacterial infection Characterization of Blood Immune Cells in Patients With Decompensated The prognostic value of acute-on-chronic liver failure during the course of severe alcoholic hepatitis Reticuloendothelial activation correlates with disease severity and predicts mortality in severe alcoholic hepatitis Von-Willebrand factor: A biomarker to predict in-hospital survival in patients with severe and very severe alcoholic hepatitis Systematic review: role of elevated plasma von-Willebrand factor as predictor of mortality in patients with chronic liver disease Determinants of Outcomes in Autoimmune Hepatitis Presenting as Acute on Chronic Liver Failure Without Extrahepatic Organ Dysfunction upon Treatment With Steroids Flare of Autoimmune Hepatitis Causing Acute on Chronic Liver Failure: Diagnosis and Response to Corticosteroid Therapy Acute-on-chronic liver failure in patients with alcohol-related liver disease Therapeutic plasma-exchange improves systemic inflammation and survival in acute-on-chronic liver failure: A propensityscore matched study from AARC High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial Standard-Volume Plasma Exchange Improves Outcomes in Patients With Acute Liver Failure: A Randomized Controlled Trial Low-volume plasma exchange and low-dose steroid to treat severe liver injury Plasma exchange in patients with acute and acute-on-chronic liver failure: A systematic review Plasma perfusion combined with plasma exchange in chronic hepatitis B-related acute-on-chronic liver failure patients Plasma exchange-centered artificial liver support system in hepatitis B virus-related acute-on-chronic liver failure: a nationwide prospective multicenter study in China Plasma exchange for acute on chronic liver failure: is there a light at the end of the tunnel? Low volume plasma exchange and low dose steroid improve survival in patients with alcohol related acute on chronic liver failure and severe alcoholic hepatitis -preliminary experience Aetiology and outcome of acute liver failure Etiopathogenesis of acute hepatic failure: Eastern versus Western countries Rodenticide ingestion is an important cause of acute hepatotoxicity in Tamil Nadu, southern India Rodenticidal hepatotoxicity: Raised plasma Von Willebrand factor levels predict in-hospital survival and preliminary report of the outcome of Von Willebrand factor reducing management protocol Effect of COVID-19 on Pre-existing Liver disease: What Hepatologist Should Know ? Endothelial cell infection and endotheliitis in COVID-19 Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 Plasma Von Willebrand Factor Levels Predict Survival in COVID-19 Patients Across the Entire Spectrum of Disease Severity Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: Consider low volume plasma exchange and low dose steroid Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort Autoimmune hepatitis triggered by COVID-19 Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?